Slide 1Research and Development in Pulmonary Fibrosis: The Future is Bright Glenn D. Rosen, M D Associate Professor of Medicine Interim Co-Chief and Program Director Pulmonary…

Slide 1Management of non naïve patients with hepatitis C "Non-Responders" 3rd Paris Hepatitis Conference, Paris, 19.01.2009 Christoph Sarrazin J. W. Goethe-University…

1. Module 3Unit 3:Changing/stopping ART A Rational Approach to a Complicated Subject 2. Objectives By the end of this session, the participants should be able to: Describe…

1. Module 3Unit 3:Changing/stopping ART A Rational Approach to a Complicated Subject 2. Objectives By the end of this session, the participants should be able to: Describe…

www.excemed.org IMPROVING THE PATIENT’S LIFE THROUGH MEDICAL EDUCATION What are the benefits of QMS for a fertility centre and how do we measure them S. Esteves Brazil…

1. Is Ofatumumab Better than Rituximab? Ofatumumab is a fully human antibody produced in transgenic mice immunized with CD20 • UK-based GlaxoSmithKline and Danish biotech…

Evolving CML Treatment Landscape Evolving CML Treatment Landscape GLEEVEC® (imatinib) approved by FDA1 TASIGNA® (nilotinib) for resistant or intolerant CP Ph+ CML approved…

Slide 1 Ibrutinib: Analysis of Pivotal Data Richard R. Furman, MD CLL Research Center Slide 2 BCR-associated Kinases: Proven Effective Therapeutic Targets Nat Rev Immunol…

Slide 1 In Defense of Intent-To-Treat Analyses in Randomized Trials Group 7: Wenchao Li, Shuang Liang, Stephen Smela, Tien Vo, Fan Wang & Michelle Warren Slide 2 Proposition…

1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1 NAME OF THE MEDICINAL PRODUCT Valdoxan 25 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated…